3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
35
Pancreatic Fistula
4
Pancreatic Ductal Adenocarcinoma
2
Bile Duct Neoplasms
2
Recurrence
1
Peritoneal Diseases
1
Periampullary Cancer
1
Pancreatitis, Chronic
1
Pancreatic Adenocarcinoma
1
Obesity
1
Neoplasm Metastasis
1
Metabolic Syndrome
1
Locally Advanced Pancreatic Adenocarcinoma
1
Jaundice, Obstructive
1
Hypoxia
1
Hemorrhage
1
Gastrointestinal Stromal Tumor of Duodenum
1
Diabetes Mellitus
1
Cholangiocarcinoma
1
Carcinoma, Pancreatic Ductal
1
Adenocarcinoma
1
Interventions
Oxaliplatin
30
Gemcitabine
28
Fluorouracil
27
Capecitabine
22
Leucovorin
19
pembrolizumab
15
130-nm albumin-bound paclitaxel
13
Irinotecan
12
Cisplatin
11
Bevacizumab
11
Albumin-Bound Paclitaxel
11
Paclitaxel
10
Ramucirumab
8
Radiotherapy
8
Docetaxel
8
Nivolumab
7
trastuzumab deruxtecan
6
Cyclophosphamide
6
Taxes
5
Drug Therapy
5
durvalumab
4
Trastuzumab
4
Metformin
4
zolbetuximab
3
spartalizumab
3
folfirinox
3
cemiplimab
3
XELOX
3
Surgical Procedures, Operative
3
Sorafenib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma
×
Pancreaticoduodenectomy
×
Gastrointestinal
×
Clear all
NCT01419002
2015-07-29
Net-Pac
CHIR-Net
Phase 3
Terminated
5 enrolled